High-dose Gemcitabine, Busulfan and Melphalan With Autologous Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma
Phase of Trial: Phase II
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Busulfan (Primary) ; Gemcitabine (Primary) ; Melphalan (Primary) ; Dexamethasone; Filgrastim; Palifermin
- Indications Multiple myeloma
- Focus Therapeutic Use
- 22 Sep 2017 Status changed from active, no longer recruiting to completed.
- 03 May 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
- 02 May 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017.